bool(false)

Butantan Institute files for CoronaVac emergency approval

. Jan 08, 2021
emergency use coronavac São Paulo officials present CoronaVac efficacy rates. Photo: GOVESP

The Brazilian National Health Surveillance Agency (Anvisa) received a request for the emergency approval of Chinese-made coronavirus vaccine CoronaVac on Friday. The petition was filed by São Paulo’s Butantan Institute — which carried out CoronaVac clinical trials in Brazil — following a deal with the federal government for 100 million doses.

Anvisa officials say clearance could come within ten days — but the agency may extend the deadline if further information is necessary.

On January 7, Butantan announced that CoronaVac has a 78-percent efficacy rate against mild Covid-19 infections — and 100 percent for severe cases. However, the institute offered no further details on the clinical trial results.

Support this coverage →Support this coverage →
 
Natália Scalzaretto

Natália Scalzaretto has worked for companies such as Santander Brasil and Reuters, where she covered news ranging from commodities to technology. Before joining The Brazilian Report, she worked as an editor for Trading News, the information division from the TradersClub investor community.

Our content is protected by copyright. Want to republish The Brazilian Report? Email us at contact@brazilian.report